



PATENT
ATTORNEY DOCKET NO. 50308/009002

Certificate of Mailing: Date of Deposit: March 26, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine M. Colbert

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Müller-Hermelink et al. Art Unit: Not Yet Assigned

Serial No.: 10/764,730 Examiner: Not Yet Assigned

Filed: January 26, 2004 Customer No.: 21559

Title: NEOPLASM-SPECIFIC POLYPEPTIDES AND THEIR USES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.


Respectfully submitted,

Date: March 26, 2004



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045




Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 50308/009002 Serial No. 10/764,730 Applicant Müller-Hermelink et al. Filing Date January 26, 2004 Group Not Assigned Yet IDS Filed March 26, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 00/37489 A2 & A3	June 29, 2000	WIPO			Yes
	WO 03/011907 A2 & A3	February 13, 2003	WIPO			Yes
	WO 03/076472 A2	September 18, 2003	WIPO			
	WO 2004/005351 A2	January 15, 2004	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Applemelk et al., "Molecular Mimicry between <i>Helicobacter pylori</i> and the Host," <i>Trends in Microbiology</i> 5(2):70-73 (1997).					
	Burrus et al., "Identification of Cysteine-Rich Receptor for Fibroblast Growth Factors," <i>Molecular and Cellular Biology</i> 12(12):5600-5609 (1992).					
	Brändlein et al., "Human Monoclonal IgM Antibodies with Apoptotic Activity Isolated from Cancer Patients," <i>Hum. Antibodies</i> 11(4):107-119 (2002).					
	Brändlein et al., "Natural IgM Antibodies and Immunosurveillance Mechanisms Against Epithelial Cancer Cells in Humans," <i>Cancer Res.</i> 63:7995-8005 (2003).					
	Brändlein et al., "Cysteine-Rich Fibroblast Growth Factor Receptor 1, a New Marker for Precancerous Epithelial Lesions Defined by the Human Monoclonal Antibody PAM-1," <i>Cancer Research</i> 63:2052-2061 (2003).					
	Brändlein et al., "CFR-1 Receptor as Target for Tumor-Specific Apoptosis Induced by the Natural Human Monoclonal Antibody PAM-1," <i>Oncology Reports</i> 11:777-784 (2004).					
	Brown and Gatter, "Ki67 Protein: the Immaculate Deception," <i>Histopathology</i> 40:2-11 (2002).					
	Claeys et al., "The Gastric H ⁺ , K ⁺ - ATPase Is a Major Autoantigen in Chronic <i>Helicobacter pylori</i> Gastritis with Body Mucosa Atrophy," <i>Gastroenterology</i> 115:340-347 (1998).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 50308/009002 Serial No. 10/764,730 Applicant Müller -Hermelink et al. Filing Date January 26, 2004 Group Not Assigned Yet IDS Filed March 26, 2004		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Crabtree et al., "Gastric Interleukin-8 and IgA IL-8 Autoantibodies in <i>Helicobacter pylori</i> Infection," <i>Scand. J. Immunol.</i> 37:65-70 (1993).					
	Endl and Gerdes, "The Ki-67 Protein: Fascinating Forms and an Unknown Function," <i>Experimental Cell Research</i> 257:231-237 (2000).					
	Gonatas et al., "Truncations of the C-Terminal Cytoplasmic Domain of MG160, a Medial Golgi Sialoglycoprotein, Result in its Partial Transport to the Plasma Membrane and Filopodia," <i>Journal of Cell Science</i> 111:249-260 (1998).					
	Hensel et al., "Mitogenic Autoantibodies in <i>Helicobacter pylori</i> -Associated Stomach Cancerogenesis," <i>Int. J. Cancer</i> 081:229-235 (1999).					
	Hensel et al., "A Novel Proliferation-Associated Variant of CFR-1 Defined by a Human Monoclonal Antibody," <i>Lab Invest.</i> 81(8):1097-1108 (2001).					
	Hensel et al., "A New Variant of Cystein-Rich FGF Receptor (CFR-1) Specifically Expressed on Tumor Cells," <i>Proceedings of the American Association for Cancer Research Annual</i> 41 pp. 698 Abstract 4438 (2000).					
	Ma et al., "Positive Correlation between H,K-Adenosine Triphosphatase Autoantibodies and <i>Helicobacter pylori</i> Antibodies in Patients with Pernicious Anemia," <i>Scand. J. Gastroenterol.</i> 29(11):961-965 (1994).					
	Mourelatos et al., "Cloning and Sequence Analysis of the Human MG160, a Fibroblast Growth Factor and E-Selectin Binding Membrane Sialoglycoprotein of the Golgi Apparatus," <i>DNA and Cell Biology</i> 15:1121-1128 (1996).					
	Negrini et al., "Antigenic Mimicry between <i>Helicobacter pylori</i> and Gastric Mucosa in the Pathogenesis of Body Atrophic Gastritis," <i>Gastroenterology</i> 111:655-665 (1996).					
	Pfaff et al., "Human Monoclonal Antibody against a Tissue Polypeptide Antigen-Related Protein from a Patient with a Signet-Ring Cell Carcinoma of the Stomach," <i>Cancer Research</i> 50:5192-5198 (1990).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50308/009002		Serial No. 10/764,730	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Müller-Hermelink et al.		Filing Date January 26, 2004	
(37 C.F.R. § 1.98(b))				Group Not Assigned Yet		IDS Filed March 26, 2004	

U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ramires et al., "Ki67 Labelling Index in Gastric Carcinomas. An Immunohistochemical Study Using Double Staining for the Evaluation of the Proliferative Activity of Diffuse-Type Carcinomas," <i>Journal of Pathology</i> 182:62-67 (1997).
	Scholzen and Gerdes, "The Ki-67 Protein: From the Known and the Unknown," <i>Journal of Cellular Physiology</i> 182:311-322 (2000).
	Smalheiser "Proteins in Unexpected Locations," <i>Molecular Biology of the Cell</i> 7:1003-1014 (1996).
	Steeigmaier et al., "The E-Selectin-Ligand ESL-1 Is a Variant of a Receptor for Fibroblast Growth Factor," <i>Nature</i> 373:615-620 (1995).
	Steeigmaier et al., "The E-Selectin-Ligand ESL-1 Is Located in the Golgi as well as on Microvilli on the Cell Surface," <i>Journal of Cell Science</i> 110:687-694 (1997).
	Steininger et al., "Apoptosis in Chronic Gastritis and its Correlation with Antigastric Autoantibodies," <i>Virchows Arch</i> 433:13-18 (1998).
	Stieber et al., "MG160, A Membrane Protein of the Golgi Apparatus which Is Homologous to a Fibroblast Growth Factor Receptor and to a Ligand for E-Selectin, Is Found only in the Golgi Apparatus and Appears early in Chicken Embryo Development," <i>Experimental Cell Research</i> 219:562-570 (1995).
	Stulle et al., "Human Stomach Carcinoma-Specific T Cells Derived from the Tumour-Draining Lymph Nodes," <i>Br. J. Cancer</i> 70:1053-1059 (1994).
	Vollmers et al., "Monoclonal Antibodies NORM-1 and NORM-2 Induce more Normal Behavior of Tumor Cells In Vitro and Reduce Tumor Growth In Vivo," <i>Cell</i> 40:547-557 (1985).
	Vollmers et al., "Human Monoclonal Antibodies from Stomach Carcinoma Patients React with <i>Helicobacter pylori</i> and Stimulate Stomach Cancer Cells in Vitro," <i>Cancer</i> 74(5):1525-1532 (1994).
	Vollmers et al., "Adjuvant Therapy for Gastric Adenocarcinoma with the Apoptosis-Inducing Human Monoclonal Antibody SC-1: First Clinical and Histopathological Results," <i>Oncology Reports</i> 5:549-552 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Sheet 4 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50308/009002	
				Serial No. 10/764,730	
				Applicant Müller-Hermelink et al.	
				Filing Date January 26, 2004	
				Group Not Assigned Yet	
				IDS Filed March 26, 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					
(37 C.F.R. § 1.98(b))					
U.S. PATENTS					
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION					
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Vollmers et al., "Nature's Best Weapons to Fight Cancer. Revival of Human Monoclonal IgM Antibodies," <i>Human Antibodies</i> 11:131-142 (2002).				
	Vollmers and Birchmeier, "Monoclonal Antibodies Inhibit the Adhesion of Mouse B 16 Melanoma Cells <i>in vitro</i> and Block Lung Metastasis <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci.</i> 80:3729-3733 (1983).				
	Zuber et al., "Cysteine-Rich FGF Receptor Regulates Intracellular FGF-1 and FGF-2 Levels," <i>Journal of Cellular Physiology</i> 170:217-227 (1997).				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					